psalexa
logo

Cervical Cancer Therapeutics Pipeline Analysis

Cervical Cancer Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11184
Available Format:

Cervical cancer is an abnormal growth of the cervix tissues. The cervix is the lower narrowed end of the uterus, also called birth canal, which leads from uterus to vagina. There are two types of cervical cancer namely squamous cell carcinoma and adenocarcinoma. Almost 80% to 90% of the of cervical cancer are squamous cell carcinoma. Squamous cell carcinoma begins in flat and thin cells that line the cervix while adenocarcinoma begins in the cervical cells that make mucus and other fluids. The most significant cause of cervical cancer is the long-lasting infection of human papilloma virus (HPV). Almost 90% of the cases on cervical cancer involve infection due to HPV. The vaccine that protect against infection of HPV can greatly reduce the risk of cervical cancer. The cervical cancer has high treatment rate if found and treated early. Cervical cancer is usually slow growing and may not cause early symptoms, but it can be found early with pap tests.

The drug candidates of cervical cancer pipeline include, but are not limited to, ISA101, AGEN2034 and Z-100. Some of the companies developing drugs for the treatment of cervical cancer are Isa Pharmaceuticals B.V., Advaxis Inc., Zeria Pharmaceutical Co., Ltd., and Transgene SA.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry